Share This Page
chloroquine phosphate; primaquine phosphate - Profile
✉ Email this page to a colleague
What are the generic sources for chloroquine phosphate; primaquine phosphate and what is the scope of freedom to operate?
Chloroquine phosphate; primaquine phosphate
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for chloroquine phosphate; primaquine phosphate
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for chloroquine phosphate; primaquine phosphate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE | chloroquine phosphate; primaquine phosphate | TABLET;ORAL | 014860-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Investment Scenario and Fundamentals Analysis: Chloroquine Phosphate and Primaquine Phosphate
What is the investable drug product set?
Chloroquine phosphate and primaquine phosphate are small-molecule antimalarials sold as oral tablets under generic status in most markets. The investor-relevant question is not “new molecule upside,” but durable regulatory status, supply stability, and payer demand tied to malaria burden and guideline positioning.
Drug basics (active ingredients)
| Active ingredient | Typical therapeutic role (market context) | Core payer drivers | Primary investment bottleneck |
|---|---|---|---|
| Chloroquine phosphate | Blood-stage malaria treatment in chloroquine-sensitive settings; resistance-limited use in many regions | Subsidized malaria programs; procurement volumes in sensitive geographies | Continued relevance vs resistance patterns and guideline shifts |
| Primaquine phosphate | Radical cure for P. vivax and P. ovale (and gametocytocidal use in transmission control) | Adherence to radical cure policies; hemolysis safety controls | G6PD testing access and safety/regulatory constraints |
Mechanistic pairing in policy: Primaquine is used to clear liver hypnozoites (radical cure), while chloroquine targets blood-stage infection. This split aligns with how malaria control programs structure procurement and distribution. (Guideline positioning reflected in WHO malaria guidance.) [1], [2]
What is the clinical and regulatory demand structure?
1) Chloroquine phosphate demand is conditional on resistance
Chloroquine’s commercial “addressable market” is narrower than it used to be due to widespread resistance to Plasmodium falciparum across many endemic regions. Where resistance remains low (often specific geographies or constrained use protocols), chloroquine still appears in treatment algorithms. WHO guidance reflects continued use in selected settings and emphasizes local resistance patterns. [1]
2) Primaquine phosphate demand is anchored to vivax and ovale radical cure
Primaquine is used for P. vivax and P. ovale relapse prevention and transmission-blocking intent via gametocytocidal activity. This keeps demand tied to:
- prevalence of vivax and ovale species,
- public health policy adoption,
- and the ability to operationalize hemolysis risk management through G6PD testing.
WHO guidance places primaquine radical cure within a structured safety approach. [1], [2]
3) Safety and monitoring reshape utilization rates
Primaquine can cause hemolysis in G6PD deficiency. Market execution depends on whether G6PD testing is available or whether programs run supervised regimens with appropriate safeguards. WHO explicitly addresses safety considerations in its malaria guidance. [1], [2]
How do WHO malaria guidelines translate into purchasing behavior?
Procurement behavior usually follows guideline language and national malaria program protocols. Those protocols typically align with WHO treatment recommendations, which treat:
- chloroquine as a resistance-conditional blood-stage therapy,
- primaquine as a core tool for vivax/ovale radical cure and related transmission control.
WHO’s malaria recommendations and treatment guidance repeatedly emphasize the role of primaquine in relapse prevention and the need for hemolysis precautions tied to G6PD status. [1], [2]
Practical implications for fundamentals
- Primaquine volume stability tends to be higher than chloroquine in many markets because vivax/ovale radical cure is policy-driven, even when blood-stage therapies shift.
- Chloroquine volume is more policy-sensitive because falciparum resistance and first-line updates can reduce procurement in non-susceptible settings.
Where are the commercial floor and ceiling?
Commercial floor: public health procurement
For generics, revenue stability often tracks:
- malaria incidence and program budgets,
- tender cycles,
- and essential medicines lists that anchor procurement.
WHO maintains malaria guidance that influences national formularies and program treatment choices. [1], [2]
Commercial ceiling: competitive substitution
- Chloroquine is substitute-able where resistance exists (and where ACT regimens dominate falciparum management).
- Primaquine competes mainly on protocol acceptability and supply reliability, not molecule uniqueness, because alternative radical cure agents are used less broadly than primaquine in many settings and are constrained by policy adoption.
What is the investment case: base-case, bear-case, and bull-case?
Base case (most likely)
- Primaquine phosphate retains consistent procurement in vivax/ovale burden geographies.
- Chloroquine phosphate sells where susceptibility or legacy protocols persist.
- Margin profile stays typical for generics: cost pressure, tender-driven pricing, and inventory management dominate earnings.
Demand remains anchored to WHO-aligned malaria strategy and species prevalence. [1]
Bear case
- Continued guideline tightening and national protocol updates reduce chloroquine utilization further in marginal geographies.
- Operational constraints (G6PD testing access) reduce primaquine eligibility, forcing dose delays, exclusions, or substitution.
WHO emphasizes safety and hemolysis management, which creates program execution friction. [1], [2]
Bull case
- Programs adopt broader vivax/ovale radical cure coverage, raising primaquine eligible patient share.
- Supply consolidation or disruptions increase buyer reliance on available generic sources, improving pricing power for qualified manufacturers.
How do pricing and margin dynamics work in practice for generics?
The market economics for these two actives typically reflect:
- tender pricing with periodic renegotiations,
- supply assurance requirements for public buyers,
- and regulatory quality as a gating factor for inclusion.
For investors, fundamentals usually hinge on whether a manufacturer can:
- pass quality audits,
- maintain stable API and finished dose supply,
- and meet bioequivalence/quality package standards for each destination market.
What patent and exclusivity constraints matter (and what usually does not)?
Chloroquine phosphate and primaquine phosphate are older actives that generally sit outside meaningful, molecule-level patent protection in most jurisdictions. The investment relevance shifts to:
- process patents (if any still active for specific manufacturing steps),
- formulation and fixed-dose combinations (only where not fully genericized),
- local patents tied to specific dosing regimens and product presentations,
- and regulatory exclusivities that may still protect certain branded products in limited markets.
Given generic dominance, investing in production capacity, regulatory readiness, and supply chain resilience tends to matter more than novel patent landscapes for these actives.
Key fundamentals checklist (investment-grade)
Use this as a go/no-go lens for funding, partnership, or acquisition underwriting.
Demand fundamentals
- Evidence of vivax/ovale burden in target procurement geographies (primaquine pull).
- Evidence of chloroquine sensitivity or legacy regimen persistence in target geographies (chloroquine pull).
- National alignment to WHO malaria recommendations and treatment algorithms. [1], [2]
Safety and eligibility operations
- G6PD testing availability and program operational workflow maturity (primaquine utilization). [1], [2]
- Labeling compliance and pharmacovigilance infrastructure for hemolysis risk.
Commercial execution
- Qualification status with large buyers and panel listings.
- Tender track record and ability to deliver to specification with consistent lot acceptance.
Supply chain economics
- API sourcing stability for both actives.
- Finished dose manufacturing capacity and yield.
- Logistics readiness for tropical climates and shelf-life management.
What is the investment scenario summary?
Positioning map
| Dimension | Chloroquine phosphate | Primaquine phosphate |
|---|---|---|
| Core demand | Blood-stage malaria treatment in selected resistance contexts | Radical cure and related transmission control for vivax/ovale |
| Guideline dependence | High, especially on resistance patterns | High, via radical cure policy and safety protocols |
| Program friction | Moderate (therapy positioning) | High (G6PD testing and hemolysis risk controls) |
| Competitive pressure | High where ACT first-line dominates | High generic competition, but policy-driven indication supports steady procurement |
| Best investor angle | Supply assurance plus targeted geographies where chloroquine remains used | Program adoption enabler plus reliable supply into vivax radical cure channels |
WHO malaria guidance anchors both roles and safety framing for primaquine. [1], [2]
Key Takeaways
- Primaquine phosphate has the steadier policy-linked demand profile due to vivax and ovale radical cure and transmission control positioning in WHO malaria guidance. [1], [2]
- Chloroquine phosphate faces more variable demand because its therapeutic use is resistance-conditional and can be displaced in favor of ACT-based regimens where chloroquine resistance is high. [1]
- Investment fundamentals for these generics prioritize procurement dynamics, safety operations (G6PD testing readiness), and supply reliability, not molecule patent upside. [1], [2]
FAQs
1) Is there meaningful patent upside for chloroquine phosphate and primaquine phosphate?
In most markets, these actives are widely genericized, so investment upside usually does not come from molecule-level exclusivity but from manufacturing, regulatory standing, and any residual local/formulation/process IP tied to specific products.
2) What most determines primaquine phosphate procurement volumes?
Whether national malaria programs implement vivax/ovale radical cure and can manage hemolysis risk via G6PD testing and safeguards, consistent with WHO guidance. [1], [2]
3) Why is chloroquine phosphate demand more volatile than primaquine?
Chloroquine efficacy and national treatment placement depend heavily on local resistance patterns, which can shift treatment algorithms over time. [1]
4) Does investor risk center on clinical failure or operational execution?
For these generic actives, the dominant risks tend to be operational: tender acceptance, lot quality, supply continuity, and safety eligibility procedures rather than new clinical efficacy uncertainty. (WHO safety framing for primaquine drives part of this operational complexity.) [1], [2]
5) What buyers are most likely to influence the revenue cycle?
Public health procurement entities tied to national malaria programs, which follow treatment guidance aligned with WHO recommendations. [1], [2]
References
[1] World Health Organization. (2023). Guidelines for malaria. WHO.
[2] World Health Organization. (2024). World malaria report 2024. WHO.
More… ↓
